Publikationen (30) Publikationen, an denen Forscher/innen teilgenommen haben

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

    Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

  3. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  4. Adolescent Reference Values for MR-Derived Biventricular Strain Obtained Using Feature-Tracking and Myocardial Tagging

    Journal of Magnetic Resonance Imaging

  5. AulaGinecología.com: A new educational tool in gynecology and obstetrics

    Educacion Medica, Vol. 25, Núm. 2

  6. CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation

    Virchows Archiv

  7. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

    ESMO Open, Vol. 9, Núm. 3

  8. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

  9. Confirmatory study of the usefulness of quantum molecular resonance and microdissectomy for the treatment of lumbar radiculopathy in a prospective cohort at 6 months follow-up

    Scandinavian Journal of Pain, Vol. 24, Núm. 1

  10. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119

    Journal of Pathology: Clinical Research, Vol. 10, Núm. 3

  11. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

  12. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

  13. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

    Annals of Oncology

  14. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology, Vol. 195

  15. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

  16. Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

  17. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

    Clinical Cancer Research, Vol. 30, Núm. 6, pp. 1093-1103

  18. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355

    Journal of the National Cancer Institute, Vol. 116, Núm. 5, pp. 717-727

  19. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

  20. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

    Clinical and Translational Oncology